In this study, the investigators test 2 dose levels of thiotepa (5 mg/kg and 10 mg/kg) added to the backbone of targeted reduced dose IV busulfan, fludarabine and rabbit anti-thymocyte globulin (rATG) to determine the minimum effective dose required for reliable engraftment for subjects undergoing hematopoietic stem cell transplantation for non-malignant disease.
Full Title of Study: “PEDS024, Phase I/II Feasibility Study of Busulfan Fludarabine and Thiotepa Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation (HSCT) for Children With Non-Malignant Disorders”
- Study Type: Interventional
- Study Design
- Allocation: Randomized
- Intervention Model: Sequential Assignment
- Primary Purpose: Treatment
- Masking: None (Open Label)
- Study Primary Completion Date: June 2021
Hematopoietic stem cell transplantation is the only curative choice for a number of inherited bone marrow failure syndromes, hemoglobinopathies, metabolic disorders and primary immune deficiencies. While survival of these patients is typically better than survival of patients with malignancies, toxicities of conditioning regimens and failure of engraftment remain challenges. Most children with non-malignant disorders present with normocellular or even hypercellular bone marrow, posing a barrier to engraftment and requiring intensive conditioning. Commonly used backbone of busulfan and fludarabine, although well tolerated, results in variable engraftment, in particular with mismatched unrelated donors and cord blood recipients. In this study, the investigators test 2 dose levels of thiotepa (5 mg/kg and 10 mg/kg) added to the backbone of targeted reduced dose IV busulfan, fludarabine and rabbit anti-thymocyte globulin (rATG) in order to determine the minimum effective dose required for reliable engraftment. Subjects are stratified in groups A and B based the risk of graft failure.
- Drug: Thiotepa–single daily dose
- Conditioning regimen for hematopoietic stem-cell transplant. Single daily IV dose of Thiotepa at 5 mg/kg.
- Drug: Thiotepa–escalated dose
- Twice daily IV dose of Thiotepa at 5 mg/kg, twelve hours apart, 10mg/kg total.
Arms, Groups and Cohorts
- Experimental: Group A–Thiotepa single dose
- Fully matched 10/10 subjects with lower risk of graft failure. Subjects will undergo 10/10 HLA (human leukocyte antigen) matched bone marrow and peripheral blood transplant. Subjects receive combination of single daily dose thiotepa (5 mg/kg) added to the backbone of targeted reduced dose IV busulfan, fludarabine and rabbit anti-thymocyte globulin (rATG).
- Experimental: Group A–Thiotepa escalated dose
- Fully matched 10/10 subjects with lower risk of graft failure. Subjects will undergo 10/10 HLA (human leukocyte antigen) matched bone marrow and peripheral blood transplant. Subjects receive combination of escalated dose of thiotepa (10 mg/kg) added to the backbone of targeted reduced dose IV busulfan, fludarabine and rabbit anti-thymocyte globulin (rATG).
- Active Comparator: Group B–Thiotepa single dose
- Subjects with higher risk of graft failure. Subjects will undergo transplant with <10/10 bone marrow or peripheral blood match, or receiving cord blood transplant. Subjects receive combination of single daily dose thiotepa (5 mg/kg) added to the backbone of targeted reduced dose IV busulfan, fludarabine and rabbit anti-thymocyte globulin (rATG).
- Active Comparator: Group B–Thiotepa escalated dose
- Subjects with higher risk of graft failure. Subjects will undergo transplant with <10/10 bone marrow or peripheral blood match, or receiving cord blood transplant. Subjects receive combination of escalated dose of thiotepa (10 mg/kg)added to the backbone of targeted reduced dose IV busulfan, fludarabine and rabbit anti-thymocyte globulin (rATG).
Clinical Trial Outcome Measures
- Assessment of minimum effective dose (MED) of Thiotepa
- Time Frame: Day 42
- Assess the MED of thiotepa in combination with reduced-dose busulfan, fludarabine and rATG required to achieve engraftment in >90% subjects undergoing hematopoietic stem cell transplantation for non-malignant disorders.
- Evaluation of risk of graft rejection/failure.
- Time Frame: Day 42; Day 365
- Change in confidence interval (CI) of all subjects who initiated conditioning regimen and have sustained engraftment failure.
- Evaluation of disease free survival (DFS)
- Time Frame: Month 12; Month 24
- Change in confidence interval (CI) of all subjects who initiated conditioning regimen and are without evidence of underlying disease (DFS).
- Evaluation of overall survival (OS)
- Time Frame: Month 12; Month 24
- Change in confidence interval (CI) of all subjects who initiated conditioning regimen and are alive (OS).
- Evaluation of transplant-related mortality
- Time Frame: Day 100; Month 12
- Change in CI of subjects who initiated conditioning regimen and who die due to a cause unrelated to the underlying disease.
- Rate of acute graft-versus-host disease (GVDH) scale
- Time Frame: Month 12
- Rank of Modified Glucksberg Staging Criteria. (Scale 0-4; with 4 being most severe)
- Rate of chronic graft-versus-host disease (cGVHD) scale
- Time Frame: Month 24
- Rank of cGVHD grading. (Scale mild, moderate, severe)
- Change in transplant-related complications
- Time Frame: Month 12; Month 24
- Complications gathered via CIBMTR (Center for International Blood & Marrow Transplant Research) post-transplant form will be tabulated and described by treatment received.
Participating in This Clinical Trial
- Diagnoses: – Hemoglobinopathies (e.g. thalassemia or sickle cell disease), – Cytopenias (e.g.Diamond-Blackfan anemia, congenital or acquired neutropenia, congenital or acquired thrombocytopenia, congenital or acquired anemia, and others, regardless clonality), – Hemophagocytic lymphohistiocytosis, – Primary immunodeficiencies (e.g. Wiscott Aldrich Syndrome, chronic granulomatous disease, common variable immune deficiency, X-linked lymphoproliferative disease, NK+ severe combined immune deficiencies), – Metabolic disorders (Hurler's syndrome, mannosidosis, adrenal leuko-dystrophy) – Other non-malignant disorders for which there is published evidence that HSCT (hematopoietic stem cell transplant) is a curative therapy. – Donor Requirements – Related or unrelated donor who is suitable and willing to donate bone marrow or peripheral blood stem cells. HLA typing should be done by high-resolution typing at A, B, C, DrB1 and DQ loci and the donor should be at a minimum ≥8/10 match (with one antigen/allele mismatch allowed at A, B, or C-loci and other at DQ loci). – Cord blood units must be matched at a minimum of 6/8 antigens/alleles at A, B, C and DrB1 loci. High resolution typing at all loci is required. The minimum TNC dose pre-cryopreservation must be ≥3.7 x10^7/kg of recipient's weight, if a single cord blood unit is used, or at least 2×10^7/kg per unit, if two cord blood units are used. The mismatches cannot be at the same loci (e.g. double A mismatch). – Haploidentical related stem cell donor who is suitable and willing to donate peripheral blood stem cells. T-cell depletion is required if haploidentical donors are used. Pharmacologic GVHD prophylaxis will not be used for T-cell depleted transplant recipients. – Adequate organ function defined as: – Cardiac: ejection fraction ≥55% or shortening fraction ≥30% – creatinine clearance ≥70 ml/min/1.73m2 – Pulse oximetry >95% on room air or FEV1/DLCO >60% – LFTs < 3 x ULN, Total bilirubin <3 mg/dl (unless due to non-hepatic cause (e.g. Gilbert's syndrome or hemolysis) – Lansky/Karnofsky score ≥60% – Written informed consent obtained from the subject or parental/guardian permission ± child's assent per institutional guidelines – Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy for at least 1 month after completion of conditioning. WOCBP include any woman who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or who is not post-menopausal. Post-menopause is defined as: – Amenorrhea that has lasted for ≥ 12 consecutive months without another cause, or – For women with irregular menstrual periods who are taking hormone replacement therapy (HRT), a documented serum follicle-stimulating hormone (FSH) level of greater than 35 mIU/mL. – Males with female partners of childbearing potential must agree to use physician-approved contraceptive methods (e.g., abstinence, condoms, or vasectomy) for at least one month after completion of conditioning. Exclusion Criteria:
- Diagnoses that do not require myeloablative transplant for cure (e.g. NK- SCID patients), unless the subject previously did not engraft with non-myeloablative or reduced intensity conditioning transplant. – Known or suspected sensitivity to chemotherapy or radiation (e.g Fanconi's anemia, Dyskeratosis congenita, Ligase IV deficiency, etc). – Subjects with fast-progressing neurodegenerative disorders (e.g. Krabbe disease or adrenal leukodystrophy with Loes score of ≥10) – Cytopenias with increased blasts (>5%) – Presence of anti-donor HLA antibodies (positive anti-donor HLA antibody is defined as a positive cross-match test of any titer (by complement-dependent cytotoxicity or flow cytometric testing) or the presence of anti-donor HLA antibody to the high expression loci HLA-A, B, C, DRB1 with mean fluorescence intensity (MFI)>3000 by solid phase – Prior allogeneic stem cell transplant, except for patients with immune deficiencies who underwent previous non-myeloablative or reduced intensity transplants. – Haploidentical donor using in vivo T-cell depletion (e.g. post-transplant cyclophosphamide). – Uncontrolled bacterial, viral, or fungal infection at the time of enrollment. Uncontrolled is defined as currently taking medication and with progression or no clinical improvement on adequate medical treatment. – Seropositive for HIV – Active Hepatitis B or C determined by a detectable viral load of HBV or HCV by PCR – Bridging fibrosis or liver cirrhosis – Females or males of childbearing potential who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for at least 1 months after the end of conditioning – Females who are pregnant or breastfeeding – History of any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of protocol therapy or that might affect the interpretation of the results of the study or that puts the subject at high risk for treatment complications, in the opinion of the treating physician. – Subjects demonstrating an inability to understand the study and comply with the study and/or follow-up procedures
Gender Eligibility: All
Minimum Age: 3 Months
Maximum Age: 39 Years
Are Healthy Volunteers Accepted: No
- Lead Sponsor
- University of Florida
- Live Like Bella Pediatric Cancer Research
- Provider of Information About this Clinical Study
- Overall Official(s)
- Biljana Horn, MD, Principal Investigator, University of Florida
- Overall Contact(s)
- Giselle Moore-Higgs, PhD, 3522739050, email@example.com
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.